Almagor Tal, Rath Shoshana, Nachtigal Dan, Sharroni Zohara, Elias-Assad Ghadir, Hess Ora, Havazelet Gilad, Zehavi Yoav, Spiegel Ronen, Bercovich Dani, Almashanu Shlomo, Tenenbaum-Rakover Yardena
Pediatric Endocrine Institute, Ha'Emek Medical Center, Afula, Israel.
Pediatric Department B, Ha'Emek Medical Center, Afula, Israel.
Eur Thyroid J. 2021 Jun;10(3):215-221. doi: 10.1159/000509775. Epub 2020 Sep 3.
An association between hearing impairment (HI) and congenital hypothyroidism (CH) has been reported previously. However, in general, studies were retrospective and had small sample sizes, and the results were variable and inconclusive. The aim of our study was to assess the prevalence of HI among patients with CH and to examine factors potentially predictive of HI including severity of CH, etiology of CH, and timing of treatment initiation.
Audiometry was undertaken prospectively in 66 patients aged 3-21 years diagnosed with primary CH and 49 healthy matched controls. All patients with HI underwent examination by an otolaryngologist, and in patients with sensorineural loss, brainstem evoked response audiometry was performed. A next-generation sequencing (NGS) panel for genes involved in deafness was performed in patients with sensorineural HI to exclude additional genetic etiologies.
HI was found in 19 patients (28.7%). Among them, 5 (7.6%) had moderate to severe bilateral sensorineural impairment and 14 (21.2%) had mild conductive HI. Conductive HI was bilateral in 5 of these patients (36%). None of the controls had HI. No specific etiology was found in patients with HI, and no differences were identified in age at diagnosis, age at initiation of levothyroxine (LT) therapy, gender, or ethnicity between patients with and without HI. A nonsignificant trend toward lower mean screening TT levels was found in patients with HI (compared to those without HI) (3.42 vs. 5.34 μg/dL, = 0.095). No pathogenic variants in genes attributed to HI were identified by NGS in the 5 patients with sensorineural deafness, indicating that HI in these patients was likely attributable to CH rather than other genetic etiologies.
Our findings indicate a high prevalence of HI among patients with CH, predominantly of the conductive type. HI was not associated with the etiology of CH or with delayed initiation of LT therapy. Audiometry is recommended for children diagnosed with CH and repeat monitoring may be warranted to identify acquired HI and to prevent long-term sequelae of undiagnosed deafness.
先前已有报道称听力障碍(HI)与先天性甲状腺功能减退症(CH)之间存在关联。然而,总体而言,研究多为回顾性研究且样本量较小,结果不一且尚无定论。我们研究的目的是评估CH患者中HI的患病率,并检查可能预测HI的因素,包括CH的严重程度、CH的病因以及开始治疗的时间。
对66例年龄在3至21岁、诊断为原发性CH的患者及49例健康匹配对照进行前瞻性听力测定。所有HI患者均由耳鼻喉科医生进行检查,对于感音神经性听力损失患者,进行脑干诱发电位听力测定。对感音神经性HI患者进行与耳聋相关基因的下一代测序(NGS)检测,以排除其他遗传病因。
19例患者(28.7%)存在HI。其中,5例(7.6%)有中度至重度双侧感音神经性损害,14例(21.2%)有轻度传导性HI。这些患者中有5例(36%)的传导性HI为双侧性。对照组无一例有HI。HI患者未发现特定病因,有HI和无HI患者在诊断年龄、左甲状腺素(LT)治疗开始年龄、性别或种族方面均未发现差异。HI患者(与无HI患者相比)的平均筛查TT水平有降低的趋势,但差异无统计学意义(3.42 vs. 5.34 μg/dL,P = 0.095)。在5例感音神经性耳聋患者中,NGS未发现与HI相关基因的致病变异,表明这些患者的HI可能归因于CH而非其他遗传病因。
我们的研究结果表明CH患者中HI的患病率较高,主要为传导性类型。HI与CH的病因或LT治疗延迟无关。建议对诊断为CH的儿童进行听力测定,可能有必要进行重复监测,以识别获得性HI并预防未诊断耳聋的长期后遗症。